
Merck to Acquire SpringWorks Therapeutics
Merck has entered into a definitive agreement to acquire SpringWorks Therapeutics, Inc. for $47 per share in cash. The deal values SpringWorks at approximately $3.9 billion, representing a 26% premium to its 20-day volume-weighted average price before transaction speculation began. The